Search

Your search keyword '"Verma, Swapna"' showing total 799 results
Start Over Author "Verma, Swapna"
799 results on '"Verma, Swapna"'

1. The Public Health Impact and Policy Implications of Online Support Group Use for Mental Health in Singapore: Cross-Sectional Survey

Author

Roystonn, Kumarasan, Vaingankar, Janhavi Ajit, Chua, Boon Yiang, Sambasivam, Rajeswari, Shafie, Saleha, Jeyagurunathan, Anitha, Verma, Swapna, Abdin, Edimansyah, Chong, Siow Ann, and Subramaniam, Mythily

Subjects
Psychology, BF1-990
Abstract

BackgroundThe wide mental health treatment gap continues to pose a global and local public health challenge. Online support groups are on the rise and could be used to complement formal treatment services for mental health. ObjectiveThis study aimed to examine the prevalence of online support group use and explore factors associated with the use in the general population using data from a national cross-sectional mental health survey in Singapore. MethodsSingapore residents aged 18 years and above participated in a nationally representative household survey in which the World Health Organization Composite International Diagnostic Interview 3.0 was administered by trained interviewers to examine the use of online support groups for mental health. Multiple logistic regressions were used to analyze the association of online support group use with various sociodemographic and health factors. ResultsA total of 6110 respondents with complete data were included in this study. Overall, 10 individuals per 1000 adults (1%) reported seeking help from online support groups for their mental health problems. Compared to younger adults (those aged 18 to 34 years) and those with university education, individuals aged 50 to 64 years (P

Published
2020
Full Text
View/download PDF

2. Proteomic Biomarkers for the Prediction of Transition to Psychosis in Individuals at Clinical High Risk: A Multi-cohort Model Development Study.

Author

Byrne, Jonah, Healy, Colm, Föcking, Melanie, Susai, Subash, Mongan, David, Wynne, Kieran, Kodosaki, Eleftheria, Heurich, Meike, de Haan, Lieuwe, Hickie, Ian, Smesny, Stefan, Thompson, Andrew, Markulev, Connie, Young, Alison, Schäfer, Miriam, Riecher-Rössler, Anita, Mossaheb, Nilufar, Berger, Gregor, Schlögelhofer, Monika, Nordentoft, Merete, Chen, Eric, Verma, Swapna, Nieman, Dorien, Woods, Scott, Cornblatt, Barbara, Stone, William, Addington, Jean, Walker, Elaine, Cannon, Tyrone, Cannon, Mary, McGorry, Pat, Amminger, Paul, Cagney, Gerard, Nelson, Barnaby, Jeffries, Clark, Perkins, Diana, Cotter, David, Mathalon, Daniel, Bearden, Carrie, and Cadenhead, Kristin

Subjects
coagulation, complement, high risk, immune, model, prediction, proteome, psychosis, Humans, Psychotic Disorders, Female, Male, Biomarkers, Proteomics, Young Adult, Adolescent, Prodromal Symptoms, Adult, Disease Progression, Longitudinal Studies, Risk
Abstract

Psychosis risk prediction is one of the leading challenges in psychiatry. Previous investigations have suggested that plasma proteomic data may be useful in accurately predicting transition to psychosis in individuals at clinical high risk (CHR). We hypothesized that an a priori-specified proteomic prediction model would have strong predictive accuracy for psychosis risk and aimed to replicate longitudinal associations between plasma proteins and transition to psychosis. This study used plasma samples from participants in 3 CHR cohorts: the North American Prodrome Longitudinal Studies 2 and 3, and the NEURAPRO randomized control trial (total n = 754). Plasma proteomic data were quantified using mass spectrometry. The primary outcome was transition to psychosis over the study follow-up period. Logistic regression models were internally validated, and optimism-corrected performance metrics derived with a bootstrap procedure. In the overall sample of CHR participants (age: 18.5, SD: 3.9; 51.9% male), 20.4% (n = 154) developed psychosis within 4.4 years. The a priori-specified model showed poor risk-prediction accuracy for the development of psychosis (C-statistic: 0.51 [95% CI: 0.50, 0.59], calibration slope: 0.45). At a group level, Complement C8B, C4B, C5, and leucine-rich α-2 glycoprotein 1 (LRG1) were associated with transition to psychosis but did not surpass correction for multiple comparisons. This study did not confirm the findings from a previous proteomic prediction model of transition from CHR to psychosis. Certain complement proteins may be weakly associated with transition at a group level. Previous findings, derived from small samples, should be interpreted with caution.

Published
2024

3. Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis.

Author

Wannan, Cassandra, Nelson, Barnaby, Addington, Jean, Allott, Kelly, Anticevic, Alan, Arango, Celso, Baker, Justin, McGorry, Patrick, Mittal, Vijay, Nordentoft, Merete, Nunez, Angela, Pasternak, Ofer, Pearlson, Godfrey, Perez, Jesus, Perkins, Diana, Powers, Albert, Roalf, David, Sabb, Fred, Schiffman, Jason, Shah, Jai, Smesny, Stefan, Spark, Jessica, Stone, William, Strauss, Gregory, Tamayo, Zailyn, Torous, John, Upthegrove, Rachel, Vangel, Mark, Verma, Swapna, Wang, Jijun, Rossum, Inge, Wolf, Daniel, Wolff, Phillip, Wood, Stephen, Yung, Alison, Agurto, Carla, Alvarez-Jimenez, Mario, Amminger, Paul, Armando, Marco, Asgari-Targhi, Ameneh, Cahill, John, Carrión, Ricardo, Castro, Eduardo, Cetin-Karayumak, Suheyla, Mallar Chakravarty, M, Cho, Youngsun, Cotter, David, DAlfonso, Simon, Ennis, Michaela, Fadnavis, Shreyas, Fonteneau, Clara, Gao, Caroline, Gupta, Tina, Gur, Raquel, Gur, Ruben, Hamilton, Holly, Hoftman, Gil, Jacobs, Grace, Jarcho, Johanna, Ji, Jie, Kohler, Christian, Lalousis, Paris, Lavoie, Suzie, Lepage, Martin, Liebenthal, Einat, Mervis, Josh, Murty, Vishnu, Nicholas, Spero, Ning, Lipeng, Penzel, Nora, Poldrack, Russell, Polosecki, Pablo, Pratt, Danielle, Rabin, Rachel, Rahimi Eichi, Habiballah, Rathi, Yogesh, Reichenberg, Avraham, Reinen, Jenna, Rogers, Jack, Ruiz-Yu, Bernalyn, Scott, Isabelle, Seitz-Holland, Johanna, Srihari, Vinod, Srivastava, Agrima, Thompson, Andrew, Turetsky, Bruce, Walsh, Barbara, Whitford, Thomas, Wigman, Johanna, Yao, Beier, Yuen, Hok, Ahmed, Uzair, Byun, Andrew, Chung, Yoonho, Do, Kim, Hendricks, Larry, Huynh, Kevin, Jeffries, Clark, Lane, Erlend, and Langholm, Carsten

Subjects
clinical high risk, consortium, early detection, prediction, prevention, psychosis, Humans, Psychotic Disorders, Schizophrenia, Prospective Studies, Adult, Prodromal Symptoms, Young Adult, International Cooperation, Adolescent, Research Design, Male, Female
Abstract

This article describes the rationale, aims, and methodology of the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ). This is the largest international collaboration to date that will develop algorithms to predict trajectories and outcomes of individuals at clinical high risk (CHR) for psychosis and to advance the development and use of novel pharmacological interventions for CHR individuals. We present a description of the participating research networks and the data processing analysis and coordination center, their processes for data harmonization across 43 sites from 13 participating countries (recruitment across North America, Australia, Europe, Asia, and South America), data flow and quality assessment processes, data analyses, and the transfer of data to the National Institute of Mental Health (NIMH) Data Archive (NDA) for use by the research community. In an expected sample of approximately 2000 CHR individuals and 640 matched healthy controls, AMP SCZ will collect clinical, environmental, and cognitive data along with multimodal biomarkers, including neuroimaging, electrophysiology, fluid biospecimens, speech and facial expression samples, novel measures derived from digital health technologies including smartphone-based daily surveys, and passive sensing as well as actigraphy. The study will investigate a range of clinical outcomes over a 2-year period, including transition to psychosis, remission or persistence of CHR status, attenuated positive symptoms, persistent negative symptoms, mood and anxiety symptoms, and psychosocial functioning. The global reach of AMP SCZ and its harmonized innovative methods promise to catalyze the development of new treatments to address critical unmet clinical and public health needs in CHR individuals.

Published
2024

8. Towards a youth mental health paradigm: a perspective and roadmap

Author

Uhlhaas, Peter J., Davey, Christopher G., Mehta, Urvakhsh Meherwan, Shah, Jai, Torous, John, Allen, Nicholas B., Avenevoli, Shelli, Bella-Awusah, Tolulope, Chanen, Andrew, Chen, Eric Y. H., Correll, Christoph U., Do, Kim Q., Fisher, Helen L., Frangou, Sophia, Hickie, Ian B., Keshavan, Matcheri S., Konrad, Kerstin, Lee, Francis S., Liu, Cindy H., Luna, Beatriz, McGorry, Patrick D., Meyer-Lindenberg, Andreas, Nordentoft, Merete, Öngür, Dost, Patton, George C., Paus, Tomáš, Reininghaus, Ulrich, Sawa, Akira, Schoenbaum, Michael, Schumann, Gunter, Srihari, Vinod H., Susser, Ezra, Verma, Swapna K., Woo, T. Wilson, Yang, Lawrence H., Yung, Alison R., and Wood, Stephen J.

Published
2023
Full Text
View/download PDF

13. Machine learning based prediction and the influence of complement – Coagulation pathway proteins on clinical outcome: Results from the NEURAPRO trial

Author

Susai, Subash Raj, Mongan, David, Healy, Colm, Cannon, Mary, Cagney, Gerard, Wynne, Kieran, Byrne, Jonah F., Markulev, Connie, Schäfer, Miriam R., Berger, Maximus, Mossaheb, Nilufar, Schlögelhofer, Monika, Smesny, Stefan, Hickie, Ian B., Berger, Gregor E., Chen, Eric Y.H., de Haan, Lieuwe, Nieman, Dorien H., Nordentoft, Merete, Riecher-Rössler, Anita, Verma, Swapna, Street, Rebekah, Thompson, Andrew, Ruth Yung, Alison, Nelson, Barnaby, McGorry, Patrick D., Föcking, Melanie, Paul Amminger, G., and Cotter, David

Published
2022
Full Text
View/download PDF

15. Understanding Emotion Regulation Strategies Among Youths: A Qualitative Study.

Author

Chang, Sherilyn, Vaingankar, Janhavi Ajit, Seow, Esmond, Samari, Ellaisha, Chua, Yi Chian, Luo, Nan, Verma, Swapna, and Subramaniam, Mythily

Subjects
EMOTION regulation, OPTIMISM, CATHARSIS, THEMATIC analysis, EMOTIONS
Abstract

The period of youth encompasses a myriad of experiences that often elicit a range of emotions from the individual. This study was conducted to understand emotion regulation (ER) among youths, specifically to identify strategies employed by youths to regulate emotions, and to understand the perceived importance and impact of ER. Qualitative data were collected through one-to-one semi-structured interviews (n = 25) and focus group discussions (n = 11; total 70 participants) among youths aged between 15 and 24 years. Interviews were transcribed verbatim and inductive thematic analysis was used to analyze the data. ER strategies engaged by youths in this study were classified into the following themes: (1) developing emotional awareness and acceptance, (2) emotional catharsis, (3) calling for a timeout, and (4) positive thinking and reframing. Youths perceived the importance of regulating emotions as (1) ER contributes to rational thinking and decision-making, (2) poor ER worsens mental wellbeing, (3) ER provides stability in life, and has (4) relevance to current life stage and environment. Findings from this study illustrate the essential role of ER for youth's healthy functioning and demonstrate the value of strengthening emotional regulatory capacities in them. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

17. The association of plasma inflammatory markers with omega-3 fatty acids and their mediating role in psychotic symptoms and functioning: An analysis of the NEURAPRO clinical trial

Author

Susai, Subash Raj, Mongan, David, Healy, Colm, Cannon, Mary, Nelson, Barnaby, Markulev, Connie, Schäfer, Miriam R., Berger, Maximus, Mossaheb, Nilufar, Schlögelhofer, Monika, Smesny, Stefan, Hickie, Ian B., Berger, Gregor E., Chen, Eric Y.H., de Haan, Lieuwe, Nieman, Dorien H., Nordentoft, Merete, Riecher-Rössler, Anita, Verma, Swapna, Thompson, Andrew, Yung, Alison Ruth, McGorry, Patrick D., Föcking, Melanie, Cotter, David, and Amminger, G. Paul

Published
2022
Full Text
View/download PDF

19. Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis

Author

Susai, Subash Raj, Healy, Colm, Mongan, David, Heurich, Meike, Byrne, Jonah F., Cannon, Mary, Cagney, Gerard, Wynne, Kieran, Markulev, Connie, Schäfer, Miriam R., Berger, Maximus, Mossaheb, Nilufar, Schlögelhofer, Monika, Smesny, Stefan, Hickie, Ian B., Berger, Gregor E., Chen, Eric Y. H., de Haan, Lieuwe, Nieman, Dorien H., Nordentoft, Merete, Riecher-Rössler, Anita, Verma, Swapna, Street, Rebekah, Thompson, Andrew, Yung, Alison Ruth, Nelson, Barnaby, McGorry, Patrick D., Föcking, Melanie, Amminger, G. Paul, and Cotter, David

Published
2022
Full Text
View/download PDF

24. The association between migrant status and transition in an ultra-high risk for psychosis population

Author

O’Donoghue, Brian, Geros, Hellen, Sizer, Holly, Addington, Jean, Amminger, G. Paul, Beaden, Carrie E., Cadenhead, Kristin S., Cannon, Tyrone D., Cornblatt, Barbara A., Berger, Gregor Emanuel, Chen, Eric Y. H., de Haan, Lieuwe, Hartmann, Jessica A., Hickie, Ian B., Ising, Helga K., Lavoie, Suzie, Lin, Ashleigh, Markulev, Connie, Mathalon, Daniel H., McGlashan, Thomas H., Mifsud, Nathan G., Mossaheb, Nilufar, Nieman, Dorien H., Nordentoft, Merete, Perkins, Diana O., Riecher-Rössler, Anita, Schäfer, Miriam R., Schlögelhofer, Monika, Seidman, Larry J., Smesny, Stephan, Thompson, Andrew, Tsuang, Ming T., van der Gaag, Mark, Verma, Swapna, Walker, Elaine F., Wood, Stephen J., Woods, Scott W., Yuen, Hok Pan, Yung, Alison Ruth, McGorry, Patrick D., and Nelson, Barnaby

Published
2021
Full Text
View/download PDF

26. Mapping the World Health Organization Disability Assessment Scale 2.0 to the EQ-5D-5L in patients with mental disorders.

Author

Abdin, Edimansyah, Seet, Vanessa, Jeyagurunathan, Anitha, Tan, Sing Chik, Mohmad Khalid, Muhammad Iskandar Shah, Mok, Yee Ming, Verma, Swapna, and Subramaniam, Mythily

Abstract

Objective: The current study aims to develop an algorithm for mapping the WHODAS 2.0 to the EQ-5D-5 L for patients with mental disorders. Methods: This cross-sectional study was conducted at the Institute of Mental Health and Community Wellness Clinics in Singapore between June 2019 and November 2022. We included four regression methods including the Ordinary Least Square (OLS) regression, the Tobit regression model (Tobit), the robust regression with MM estimator (MM), and the adjusted limited dependent variable mixture model (ALDVMM) to map EQ-5D-5 L utility scores from the WHODAS 2.0. Results: A total of 797 participants were included. The mean EQ-5D-5 L utility and WHODAS 2.0 total scores were 0.615 (SD = 0.342) and 11.957 (SD = 8.969), respectively. We found that the EQ-5D-5 L utility score was best predicted by the robust regression model with the MM estimator. Our findings suggest that the WHODAS 2.0 total scores were significantly and inversely associated with the EQ-5D-5 L utility scores. Conclusion: This study provides a mapping algorithm for converting the WHODAS 2.0 scores into EQ-5D-5 L utility scores which can be implemented using a simple online calculator in the following web application: . [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. Supplementation with the omega-3 long chain polyunsaturated fatty acids: Changes in the concentrations of omega-3 index, fatty acids and molecular phospholipids of people at ultra high risk of developing psychosis

Author

Alqarni, Ayedh, Mitchell, Todd W., McGorry, Patrick D., Nelson, Barnaby, Markulev, Connie, Yuen, Hok Pan, Schäfer, Miriam R., Berger, Maximus, Mossaheb, Nilufar, Schlögelhofer, Monika, Smesny, Stephan, Hickie, Ian B., Berger, Gregor E., Chen, Eric Y.H., de Haan, Lieuwe, Nieman, Dorien H., Nordentoft, Merete, Riecher-Rössler, Anita, Verma, Swapna, Thompson, Andrew, Yung, Alison Ruth, Meyer, Barbara J., and Amminger, G. Paul

Published
2020
Full Text
View/download PDF

29. Comparison of erythrocyte omega-3 index, fatty acids and molecular phospholipid species in people at ultra-high risk of developing psychosis and healthy people

Author

Alqarni, Ayedh, Mitchell, Todd W., McGorry, Patrick D., Nelson, Barnaby, Markulev, Connie, Yuen, Hok Pan, Schäfer, Miriam R., Berger, Maximus, Mossaheb, Nilufar, Schlögelhofer, Monika, Smesny, Stefan, Hickie, Ian B., Berger, Gregor E., Chen, Eric Y.H., de Haan, Lieuwe, Nieman, Dorien H., Nordentoft, Merete, Riecher-Rössler, Anita, Verma, Swapna, Thompson, Andrew, Yung, Alison Ruth, Amminger, G. Paul, and Meyer, Barbara J.

Published
2020
Full Text
View/download PDF

32. Cognitive functioning in ultra-high risk for psychosis individuals with and without depression: Secondary analysis of findings from the NEURAPRO randomized clinical trial

Author

Mallawaarachchi, Sumudu Rasangi, Amminger, G. Paul, Farhall, John, Bolt, Luke K., Nelson, Barnaby, Yuen, Hok Pan, McGorry, Patrick D., Markulev, Connie, Schäfer, Miriam R., Mossaheb, Nilufar, Schlögelhofer, Monika, Smesny, Stefan, Hickie, Ian B., Berger, Gregor Emanuel, Chen, Eric Y.H., de Haan, Lieuwe, Nieman, Dorien H., Nordentoft, Merete, Riecher-Rössler, Anita, Verma, Swapna, Thompson, Andrew, Yung, Alison Ruth, and Allott, Kelly A.

Published
2020
Full Text
View/download PDF

33. The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youths at Ultra-High Risk for Psychosis

Author

Amminger, G. Paul, Nelson, Barnaby, Markulev, Connie, Yuen, Hok Pan, Schäfer, Miriam R., Berger, Maximus, Mossaheb, Nilufar, Schlögelhofer, Monika, Smesny, Stephan, Hickie, Ian B., Berger, Gregor E., Chen, Eric Y.H., de Haan, Lieuwe, Nieman, Dorien H., Nordentoft, Merete, Riecher-Rössler, Anita, Verma, Swapna, Thompson, Andrew, Yung, Alison Ruth, and McGorry, Patrick D.

Published
2020
Full Text
View/download PDF

34. Trajectories of symptom severity and functioning over a three-year period in a psychosis high-risk sample: A secondary analysis of the Neurapro trial

Author

Hartmann, Jessica A., Schmidt, Stefanie J., McGorry, Patrick D., Berger, Maximus, Berger, Gregor E., Chen, Eric Y.H., de Haan, Lieuwe, Hickie, Ian B., Lavoie, Suzie, Markulev, Connie, Mossaheb, Nilufar, Nieman, Dorien H., Nordentoft, Merete, Polari, Andrea, Riecher-Rössler, Anita, Schäfer, Miriam R., Schlögelhofer, Monika, Smesny, Stefan, Thompson, Andrew, Verma, Swapna K., Yuen, Hok Pan, Yung, Alison R., Amminger, G. Paul, and Nelson, Barnaby

Published
2020
Full Text
View/download PDF

35. Proteomic Biomarkers for the Prediction of Transition to Psychosis in Individuals at Clinical High Risk:A Multi-cohort Model Development Study

Author

Byrne, Jonah F., Healy, Colm, Föcking, Melanie, Susai, Subash Raj, Mongan, David, Wynne, Kieran, Kodosaki, Eleftheria, Heurich, Meike, de Haan, Lieuwe, Hickie, Ian B., Smesny, Stefan, Thompson, Andrew, Markulev, Connie, Young, Alison Ruth, Schäfer, Miriam R., Riecher-Rössler, Anita, Mossaheb, Nilufar, Berger, Gregor, Schlögelhofer, Monika, Nordentoft, Merete, Chen, Eric Y. H., Verma, Swapna, Nieman, Dorien H., Woods, Scott W., Cornblatt, Barbara A., Stone, William S., Mathalon, Daniel H., Bearden, Carrie E., Cadenhead, Kristin S., Addington, Jean, Walker, Elaine F., Cannon, Tyrone D., Cannon, Mary, McGorry, Pat, Amminger, Paul, Cagney, Gerard, Nelson, Barnaby, Jeffries, Clark, Perkins, Diana, Cotter, David R., Byrne, Jonah F., Healy, Colm, Föcking, Melanie, Susai, Subash Raj, Mongan, David, Wynne, Kieran, Kodosaki, Eleftheria, Heurich, Meike, de Haan, Lieuwe, Hickie, Ian B., Smesny, Stefan, Thompson, Andrew, Markulev, Connie, Young, Alison Ruth, Schäfer, Miriam R., Riecher-Rössler, Anita, Mossaheb, Nilufar, Berger, Gregor, Schlögelhofer, Monika, Nordentoft, Merete, Chen, Eric Y. H., Verma, Swapna, Nieman, Dorien H., Woods, Scott W., Cornblatt, Barbara A., Stone, William S., Mathalon, Daniel H., Bearden, Carrie E., Cadenhead, Kristin S., Addington, Jean, Walker, Elaine F., Cannon, Tyrone D., Cannon, Mary, McGorry, Pat, Amminger, Paul, Cagney, Gerard, Nelson, Barnaby, Jeffries, Clark, Perkins, Diana, and Cotter, David R.

Published
2024

36. Development and temporal validation of a clinical prediction model of transition to psychosis in individuals at ultra-high risk in the UHR 1000+ cohort

Author

Hartmann, Simon, Dwyer, Dominic, Cavve, Blake, Byrne, Enda M., Scott, Isabelle, Gao, Caroline, Wannan, Cassandra, Yuen, Hok Pan, Hartmann, Jessica, Lin, Ashleigh, Wood, Stephen J., Wigman, Johanna T.W., Middeldorp, Christel M., Thompson, Andrew, Amminger, Paul, Schlögelhofer, Monika, Riecher-Rössler, Anita, Chen, Eric Y.H., Hickie, Ian B., Phillips, Lisa J., Schäfer, Miriam R., Mossaheb, Nilufar, Smesny, Stefan, Berger, Gregor, de Haan, Lieuwe, Nordentoft, Merete, Verma, Swapna, Nieman, Dorien H., McGorry, Patrick D., Yung, Alison R., Clark, Scott R., Nelson, Barnaby, Hartmann, Simon, Dwyer, Dominic, Cavve, Blake, Byrne, Enda M., Scott, Isabelle, Gao, Caroline, Wannan, Cassandra, Yuen, Hok Pan, Hartmann, Jessica, Lin, Ashleigh, Wood, Stephen J., Wigman, Johanna T.W., Middeldorp, Christel M., Thompson, Andrew, Amminger, Paul, Schlögelhofer, Monika, Riecher-Rössler, Anita, Chen, Eric Y.H., Hickie, Ian B., Phillips, Lisa J., Schäfer, Miriam R., Mossaheb, Nilufar, Smesny, Stefan, Berger, Gregor, de Haan, Lieuwe, Nordentoft, Merete, Verma, Swapna, Nieman, Dorien H., McGorry, Patrick D., Yung, Alison R., Clark, Scott R., and Nelson, Barnaby

Abstract

The concept of ultra-high risk for psychosis (UHR) has been at the forefront of psychiatric research for several decades, with the ultimate goal of preventing the onset of psychotic disorder in high-risk individuals. Orygen (Melbourne, Australia) has led a range of observational and intervention studies in this clinical population. These datasets have now been integrated into the UHR 1000+ cohort, consisting of a sample of 1,245 UHR individuals with a follow-up period ranging from 1 to 16.7 years. This paper describes the cohort, presents a clinical prediction model of transition to psychosis in this cohort, and examines how predictive performance is affected by changes in UHR samples over time. We analyzed transition to psychosis using a Cox proportional hazards model. Clinical predictors for transition to psychosis were investigated in the entire cohort using multiple imputation and Rubin's rule. To assess performance drift over time, data from 1995-2016 were used for initial model fitting, and models were subsequently validated on data from 2017-2020. Over the follow-up period, 220 cases (17.7%) developed a psychotic disorder. Pooled hazard ratio (HR) estimates showed that the Comprehensive Assessment of At-Risk Mental States (CAARMS) Disorganized Speech subscale severity score (HR=1.12, 95% CI: 1.02-1.24, p=0.024), the CAARMS Unusual Thought Content subscale severity score (HR=1.13, 95% CI: 1.03-1.24, p=0.009), the Scale for the Assessment of Negative Symptoms (SANS) total score (HR=1.02, 95% CI: 1.00-1.03, p=0.022), the Social and Occupational Functioning Assessment Scale (SOFAS) score (HR=0.98, 95% CI: 0.97-1.00, p=0.036), and time between onset of symptoms and entry to UHR service (log transformed) (HR=1.10, 95% CI: 1.02-1.19, p=0.013) were predictive of transition to psychosis. UHR individuals who met the brief limited intermittent psychotic symptoms (BLIPS) criteria had a higher probability of transitioning to psychosis than those who met the attenuated psy, The concept of ultra-high risk for psychosis (UHR) has been at the forefront of psychiatric research for several decades, with the ultimate goal of preventing the onset of psychotic disorder in high-risk individuals. Orygen (Melbourne, Australia) has led a range of observational and intervention studies in this clinical population. These datasets have now been integrated into the UHR 1000+ cohort, consisting of a sample of 1,245 UHR individuals with a follow-up period ranging from 1 to 16.7 years. This paper describes the cohort, presents a clinical prediction model of transition to psychosis in this cohort, and examines how predictive performance is affected by changes in UHR samples over time. We analyzed transition to psychosis using a Cox proportional hazards model. Clinical predictors for transition to psychosis were investigated in the entire cohort using multiple imputation and Rubin's rule. To assess performance drift over time, data from 1995-2016 were used for initial model fitting, and models were subsequently validated on data from 2017-2020. Over the follow-up period, 220 cases (17.7%) developed a psychotic disorder. Pooled hazard ratio (HR) estimates showed that the Comprehensive Assessment of At-Risk Mental States (CAARMS) Disorganized Speech subscale severity score (HR=1.12, 95% CI: 1.02-1.24, p=0.024), the CAARMS Unusual Thought Content subscale severity score (HR=1.13, 95% CI: 1.03-1.24, p=0.009), the Scale for the Assessment of Negative Symptoms (SANS) total score (HR=1.02, 95% CI: 1.00-1.03, p=0.022), the Social and Occupational Functioning Assessment Scale (SOFAS) score (HR=0.98, 95% CI: 0.97-1.00, p=0.036), and time between onset of symptoms and entry to UHR service (log transformed) (HR=1.10, 95% CI: 1.02-1.19, p=0.013) were predictive of transition to psychosis. UHR individuals who met the brief limited intermittent psychotic symptoms (BLIPS) criteria had a higher probability of transitioning to psychosis than those who met the attenuated

Published
2024

37. Proteomic Biomarkers for the Prediction of Transition to Psychosis in Individuals at Clinical High Risk: A Multi-cohort Model Development Study

Author

Byrne, Jonah F; https://orcid.org/0000-0002-7046-0630, Healy, Colm; https://orcid.org/0000-0001-7974-1861, Föcking, Melanie, Susai, Subash Raj, Mongan, David; https://orcid.org/0000-0001-7931-9636, Wynne, Kieran, Kodosaki, Eleftheria, Heurich, Meike, de Haan, Lieuwe, Hickie, Ian B, Smesny, Stefan, Thompson, Andrew, Markulev, Connie, Young, Alison Ruth, Schäfer, Miriam R, Riecher-Rössler, Anita; https://orcid.org/0000-0001-6361-8789, Mossaheb, Nilufar, Berger, Gregor; https://orcid.org/0000-0003-2030-141X, Schlögelhofer, Monika, Nordentoft, Merete, Chen, Eric Y H, Verma, Swapna, Nieman, Dorien H, Woods, Scott W, Cornblatt, Barbara A, Stone, William S; https://orcid.org/0000-0003-2932-7288, Mathalon, Daniel H, Bearden, Carrie E; https://orcid.org/0000-0002-8516-923X, Cadenhead, Kristin S, Addington, Jean, et al, Byrne, Jonah F; https://orcid.org/0000-0002-7046-0630, Healy, Colm; https://orcid.org/0000-0001-7974-1861, Föcking, Melanie, Susai, Subash Raj, Mongan, David; https://orcid.org/0000-0001-7931-9636, Wynne, Kieran, Kodosaki, Eleftheria, Heurich, Meike, de Haan, Lieuwe, Hickie, Ian B, Smesny, Stefan, Thompson, Andrew, Markulev, Connie, Young, Alison Ruth, Schäfer, Miriam R, Riecher-Rössler, Anita; https://orcid.org/0000-0001-6361-8789, Mossaheb, Nilufar, Berger, Gregor; https://orcid.org/0000-0003-2030-141X, Schlögelhofer, Monika, Nordentoft, Merete, Chen, Eric Y H, Verma, Swapna, Nieman, Dorien H, Woods, Scott W, Cornblatt, Barbara A, Stone, William S; https://orcid.org/0000-0003-2932-7288, Mathalon, Daniel H, Bearden, Carrie E; https://orcid.org/0000-0002-8516-923X, Cadenhead, Kristin S, Addington, Jean, and et al

Published
2024

38. Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ):Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis

Author

Wannan, Cassandra M.J., Nelson, Barnaby, Addington, Jean, Allott, Kelly, Anticevic, Alan, Arango, Celso, Baker, Justin T., Bearden, Carrie E., Billah, Tashrif, Bouix, Sylvain, Broome, Matthew R., Buccilli, Kate, Cadenhead, Kristin S., Calkins, Monica E., Cannon, Tyrone D., Cecci, Guillermo, Chen, Eric Yu Hai, Cho, Kang Ik K., Choi, Jimmy, Clark, Scott R., Coleman, Michael J., Conus, Philippe, Corcoran, Cheryl M., Cornblatt, Barbara A., Diaz-Caneja, Covadonga M., Dwyer, Dominic, Ebdrup, Bjørn H., Ellman, Lauren M., Fusar-Poli, Paolo, Galindo, Liliana, Gaspar, Pablo A., Gerber, Carla, Glenthøj, Louise Birkedal, Glynn, Robert, Harms, Michael P., Horton, Leslie E., Kahn, René S., Kambeitz, Joseph, Kambeitz-Ilankovic, Lana, Kane, John M., Kapur, Tina, Keshavan, Matcheri S., Kim, Sung Wan, Koutsouleris, Nikolaos, Kubicki, Marek, Kwon, Jun Soo, Langbein, Kerstin, Lewandowski, Kathryn E., Light, Gregory A., Mamah, Daniel, Marcy, Patricia J., Mathalon, Daniel H., McGorry, Patrick D., Mittal, Vijay A., Nordentoft, Merete, Nunez, Angela, Pasternak, Ofer, Pearlson, Godfrey D., Perez, Jesus, Perkins, Diana O., Powers, Albert R., Roalf, David R., Sabb, Fred W., Schiffman, Jason, Shah, Jai L., Smesny, Stefan, Spark, Jessica, Stone, William S., Strauss, Gregory P., Tamayo, Zailyn, Torous, John, Upthegrove, Rachel, Vangel, Mark, Verma, Swapna, Wang, Jijun, Rossum, Inge Winter van, Wolf, Daniel H., Wolff, Phillip, Wood, Stephen J., Yung, Alison R., Agurto, Carla, Alvarez-Jimenez, Mario, Amminger, Paul, Armando, Marco, Asgari-Targhi, Ameneh, Cahill, John, Carrión, Ricardo E., Castro, Eduardo, Cetin-Karayumak, Suheyla, Mallar Chakravarty, M., Cho, Youngsun T., Cotter, David, D'Alfonso, Simon, Ennis, Michaela, Fadnavis, Shreyas, Fonteneau, Clara, Gao, Caroline, Gupta, Tina, Gur, Raquel E., Gur, Ruben C., Hamilton, Holly K., Hoftman, Gil D., Jacobs, Grace R., Jarcho, Johanna, Ji, Jie Lisa, Kohler, Christian G., Lalousis, Paris Alexandros, Lavoie, Suzie, Lepage, Martin, Liebenthal, Einat, Mervis, Josh, Murty, Vishnu, Nicholas, Spero C., Ning, Lipeng, Penzel, Nora, Poldrack, Russell, Polosecki, Pablo, Pratt, Danielle N., Rabin, Rachel, Rahimi Eichi, Habiballah, Rathi, Yogesh, Reichenberg, Avraham, Reinen, Jenna, Rogers, Jack, Ruiz-Yu, Bernalyn, Scott, Isabelle, Seitz-Holland, Johanna, Srihari, Vinod H., Srivastava, Agrima, Thompson, Andrew, Turetsky, Bruce I., Walsh, Barbara C., Whitford, Thomas, Wigman, Johanna T.W., Yao, Beier, Yuen, Hok Pan, Ahmed, Uzair, Byun, Andrew Jin Soo, Chung, Yoonho, Do, Kim, Hendricks, Larry, Huynh, Kevin, Jeffries, Clark, Lane, Erlend, Langholm, Carsten, Lin, Eric, Mantua, Valentina, Santorelli, Gennarina, Ruparel, Kosha, Zoupou, Eirini, Adasme, Tatiana, Addamo, Lauren, Adery, Laura, Ali, Munaza, Auther, Andrea, Aversa, Samantha, Baek, Seon Hwa, Bates, Kelly, Bathery, Alyssa, Bayer, Johanna M.M., Beedham, Rebecca, Bilgrami, Zarina, Birch, Sonia, Bonoldi, Ilaria, Borders, Owen, Borgatti, Renato, Brown, Lisa, Bruna, Alejandro, Carrington, Holly, Castillo-Passi, Rolando I., Chen, Justine, Cheng, Nicholas, Ching, Ann Ee, Clifford, Chloe, Colton, Beau Luke, Contreras, Pamela, Corral, Sebastián, Damiani, Stefano, Done, Monica, Estradé, Andrés, Etuka, Brandon Asika, Formica, Melanie, Furlan, Rachel, Geljic, Mia, Germano, Carmela, Getachew, Ruth, Goncalves, Mathias, Haidar, Anastasia, Hartmann, Jessica, Jo, Anna, John, Omar, Kerins, Sarah, Kerr, Melissa, Kesselring, Irena, Kim, Honey, Kim, Nicholas, Kinney, Kyle, Krcmar, Marija, Kotler, Elana, Lafanechere, Melanie, Lee, Clarice, Llerena, Joshua, Markiewicz, Christopher, Matnejl, Priya, Maturana, Alejandro, Mavambu, Aissata, Mayol-Troncoso, Rocío, McDonnell, Amelia, McGowan, Alessia, McLaughlin, Danielle, McIlhenny, Rebecca, McQueen, Brittany, Mebrahtu, Yohannes, Mensi, Martina, Hui, Christy Lai Ming, Suen, Yi Nam, Wong, Stephanie Ming Yin, Morrell, Neal, Omar, Mariam, Partridge, Alice, Phassouliotis, Christina, Pichiecchio, Anna, Politi, Pierluigi, Porter, Christian, Provenzani, Umberto, Prunier, Nicholas, Raj, Jasmine, Ray, Susan, Rayner, Victoria, Reyes, Manuel, Reynolds, Kate, Rush, Sage, Salinas, Cesar, Shetty, Jashmina, Snowball, Callum, Tod, Sophie, Turra-Fariña, Gabriel, Valle, Daniela, Veale, Simone, Whitson, Sarah, Wickham, Alana, Youn, Sarah, Zamorano, Francisco, Zavaglia, Elissa, Zinberg, Jamie, Woods, Scott W., Shenton, Martha E., Wannan, Cassandra M.J., Nelson, Barnaby, Addington, Jean, Allott, Kelly, Anticevic, Alan, Arango, Celso, Baker, Justin T., Bearden, Carrie E., Billah, Tashrif, Bouix, Sylvain, Broome, Matthew R., Buccilli, Kate, Cadenhead, Kristin S., Calkins, Monica E., Cannon, Tyrone D., Cecci, Guillermo, Chen, Eric Yu Hai, Cho, Kang Ik K., Choi, Jimmy, Clark, Scott R., Coleman, Michael J., Conus, Philippe, Corcoran, Cheryl M., Cornblatt, Barbara A., Diaz-Caneja, Covadonga M., Dwyer, Dominic, Ebdrup, Bjørn H., Ellman, Lauren M., Fusar-Poli, Paolo, Galindo, Liliana, Gaspar, Pablo A., Gerber, Carla, Glenthøj, Louise Birkedal, Glynn, Robert, Harms, Michael P., Horton, Leslie E., Kahn, René S., Kambeitz, Joseph, Kambeitz-Ilankovic, Lana, Kane, John M., Kapur, Tina, Keshavan, Matcheri S., Kim, Sung Wan, Koutsouleris, Nikolaos, Kubicki, Marek, Kwon, Jun Soo, Langbein, Kerstin, Lewandowski, Kathryn E., Light, Gregory A., Mamah, Daniel, Marcy, Patricia J., Mathalon, Daniel H., McGorry, Patrick D., Mittal, Vijay A., Nordentoft, Merete, Nunez, Angela, Pasternak, Ofer, Pearlson, Godfrey D., Perez, Jesus, Perkins, Diana O., Powers, Albert R., Roalf, David R., Sabb, Fred W., Schiffman, Jason, Shah, Jai L., Smesny, Stefan, Spark, Jessica, Stone, William S., Strauss, Gregory P., Tamayo, Zailyn, Torous, John, Upthegrove, Rachel, Vangel, Mark, Verma, Swapna, Wang, Jijun, Rossum, Inge Winter van, Wolf, Daniel H., Wolff, Phillip, Wood, Stephen J., Yung, Alison R., Agurto, Carla, Alvarez-Jimenez, Mario, Amminger, Paul, Armando, Marco, Asgari-Targhi, Ameneh, Cahill, John, Carrión, Ricardo E., Castro, Eduardo, Cetin-Karayumak, Suheyla, Mallar Chakravarty, M., Cho, Youngsun T., Cotter, David, D'Alfonso, Simon, Ennis, Michaela, Fadnavis, Shreyas, Fonteneau, Clara, Gao, Caroline, Gupta, Tina, Gur, Raquel E., Gur, Ruben C., Hamilton, Holly K., Hoftman, Gil D., Jacobs, Grace R., Jarcho, Johanna, Ji, Jie Lisa, Kohler, Christian G., Lalousis, Paris Alexandros, Lavoie, Suzie, Lepage, Martin, Liebenthal, Einat, Mervis, Josh, Murty, Vishnu, Nicholas, Spero C., Ning, Lipeng, Penzel, Nora, Poldrack, Russell, Polosecki, Pablo, Pratt, Danielle N., Rabin, Rachel, Rahimi Eichi, Habiballah, Rathi, Yogesh, Reichenberg, Avraham, Reinen, Jenna, Rogers, Jack, Ruiz-Yu, Bernalyn, Scott, Isabelle, Seitz-Holland, Johanna, Srihari, Vinod H., Srivastava, Agrima, Thompson, Andrew, Turetsky, Bruce I., Walsh, Barbara C., Whitford, Thomas, Wigman, Johanna T.W., Yao, Beier, Yuen, Hok Pan, Ahmed, Uzair, Byun, Andrew Jin Soo, Chung, Yoonho, Do, Kim, Hendricks, Larry, Huynh, Kevin, Jeffries, Clark, Lane, Erlend, Langholm, Carsten, Lin, Eric, Mantua, Valentina, Santorelli, Gennarina, Ruparel, Kosha, Zoupou, Eirini, Adasme, Tatiana, Addamo, Lauren, Adery, Laura, Ali, Munaza, Auther, Andrea, Aversa, Samantha, Baek, Seon Hwa, Bates, Kelly, Bathery, Alyssa, Bayer, Johanna M.M., Beedham, Rebecca, Bilgrami, Zarina, Birch, Sonia, Bonoldi, Ilaria, Borders, Owen, Borgatti, Renato, Brown, Lisa, Bruna, Alejandro, Carrington, Holly, Castillo-Passi, Rolando I., Chen, Justine, Cheng, Nicholas, Ching, Ann Ee, Clifford, Chloe, Colton, Beau Luke, Contreras, Pamela, Corral, Sebastián, Damiani, Stefano, Done, Monica, Estradé, Andrés, Etuka, Brandon Asika, Formica, Melanie, Furlan, Rachel, Geljic, Mia, Germano, Carmela, Getachew, Ruth, Goncalves, Mathias, Haidar, Anastasia, Hartmann, Jessica, Jo, Anna, John, Omar, Kerins, Sarah, Kerr, Melissa, Kesselring, Irena, Kim, Honey, Kim, Nicholas, Kinney, Kyle, Krcmar, Marija, Kotler, Elana, Lafanechere, Melanie, Lee, Clarice, Llerena, Joshua, Markiewicz, Christopher, Matnejl, Priya, Maturana, Alejandro, Mavambu, Aissata, Mayol-Troncoso, Rocío, McDonnell, Amelia, McGowan, Alessia, McLaughlin, Danielle, McIlhenny, Rebecca, McQueen, Brittany, Mebrahtu, Yohannes, Mensi, Martina, Hui, Christy Lai Ming, Suen, Yi Nam, Wong, Stephanie Ming Yin, Morrell, Neal, Omar, Mariam, Partridge, Alice, Phassouliotis, Christina, Pichiecchio, Anna, Politi, Pierluigi, Porter, Christian, Provenzani, Umberto, Prunier, Nicholas, Raj, Jasmine, Ray, Susan, Rayner, Victoria, Reyes, Manuel, Reynolds, Kate, Rush, Sage, Salinas, Cesar, Shetty, Jashmina, Snowball, Callum, Tod, Sophie, Turra-Fariña, Gabriel, Valle, Daniela, Veale, Simone, Whitson, Sarah, Wickham, Alana, Youn, Sarah, Zamorano, Francisco, Zavaglia, Elissa, Zinberg, Jamie, Woods, Scott W., and Shenton, Martha E.

Abstract

This article describes the rationale, aims, and methodology of the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ). This is the largest international collaboration to date that will develop algorithms to predict trajectories and outcomes of individuals at clinical high risk (CHR) for psychosis and to advance the development and use of novel pharmacological interventions for CHR individuals. We present a description of the participating research networks and the data processing analysis and coordination center, their processes for data harmonization across 43 sites from 13 participating countries (recruitment across North America, Australia, Europe, Asia, and South America), data flow and quality assessment processes, data analyses, and the transfer of data to the National Institute of Mental Health (NIMH) Data Archive (NDA) for use by the research community. In an expected sample of approximately 2000 CHR individuals and 640 matched healthy controls, AMP SCZ will collect clinical, environmental, and cognitive data along with multimodal biomarkers, including neuroimaging, electrophysiology, fluid biospecimens, speech and facial expression samples, novel measures derived from digital health technologies including smartphone-based daily surveys, and passive sensing as well as actigraphy. The study will investigate a range of clinical outcomes over a 2-year period, including transition to psychosis, remission or persistence of CHR status, attenuated positive symptoms, persistent negative symptoms, mood and anxiety symptoms, and psychosocial functioning. The global reach of AMP SCZ and its harmonized innovative methods promise to catalyze the development of new treatments to address critical unmet clinical and public health needs in CHR individuals., This article describes the rationale, aims, and methodology of the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ). This is the largest international collaboration to date that will develop algorithms to predict trajectories and outcomes of individuals at clinical high risk (CHR) for psychosis and to advance the development and use of novel pharmacological interventions for CHR individuals. We present a description of the participating research networks and the data processing analysis and coordination center, their processes for data harmonization across 43 sites from 13 participating countries (recruitment across North America, Australia, Europe, Asia, and South America), data flow and quality assessment processes, data analyses, and the transfer of data to the National Institute of Mental Health (NIMH) Data Archive (NDA) for use by the research community. In an expected sample of approximately 2000 CHR individuals and 640 matched healthy controls, AMP SCZ will collect clinical, environmental, and cognitive data along with multimodal biomarkers, including neuroimaging, electrophysiology, fluid biospecimens, speech and facial expression samples, novel measures derived from digital health technologies including smartphone-based daily surveys, and passive sensing as well as actigraphy. The study will investigate a range of clinical outcomes over a 2-year period, including transition to psychosis, remission or persistence of CHR status, attenuated positive symptoms, persistent negative symptoms, mood and anxiety symptoms, and psychosocial functioning. The global reach of AMP SCZ and its harmonized innovative methods promise to catalyze the development of new treatments to address critical unmet clinical and public health needs in CHR individuals.

Published
2024

43. Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trial

Author

Bolt, Luke K., Amminger, G. Paul, Farhall, John, McGorry, Patrick D., Nelson, Barnaby, Markulev, Connie, Yuen, Hok Pan, Schäfer, Miriam R., Mossaheb, Nilufar, Schlögelhofer, Monika, Smesny, Stefan, Hickie, Ian B., Berger, Gregor Emanuel, Chen, Eric Y.H., de Haan, Lieuwe, Nieman, Dorien H., Nordentoft, Merete, Riecher-Rössler, Anita, Verma, Swapna, Thompson, Andrew, Yung, Alison Ruth, and Allott, Kelly A.

Published
2019
Full Text
View/download PDF

45. The Lancet PsychiatryCommission on youth mental health

Author

McGorry, Patrick D, Mei, Cristina, Dalal, Naeem, Alvarez-Jimenez, Mario, Blakemore, Sarah-Jayne, Browne, Vivienne, Dooley, Barbara, Hickie, Ian B, Jones, Peter B, McDaid, David, Mihalopoulos, Cathrine, Wood, Stephen J, El Azzouzi, Fatima Azzahra, Fazio, Jessica, Gow, Ella, Hanjabam, Sadam, Hayes, Alan, Morris, Amelia, Pang, Elina, Paramasivam, Keerthana, Quagliato Nogueira, Isabella, Tan, Jimmy, Adelsheim, Steven, Broome, Matthew R, Cannon, Mary, Chanen, Andrew M, Chen, Eric Y H, Danese, Andrea, Davis, Maryann, Ford, Tamsin, Gonsalves, Pattie P, Hamilton, Matthew P, Henderson, Jo, John, Ann, Kay-Lambkin, Frances, Le, Long K-D, Kieling, Christian, Mac Dhonnagáin, Niall, Malla, Ashok, Nieman, Dorien H, Rickwood, Debra, Robinson, Jo, Shah, Jai L, Singh, Swaran, Soosay, Ian, Tee, Karen, Twenge, Jean, Valmaggia, Lucia, van Amelsvoort, Therese, Verma, Swapna, Wilson, Jon, Yung, Alison, Iyer, Srividya N, and Killackey, Eóin

Published
2024
Full Text
View/download PDF

46. The relationship between therapeutic alliance, frequency of consultation and uptake of telemedicine among patients seeking treatment for early psychosis: A moderated mediation model

Author

AshaRani, PV, primary, Tan, Yeow Wee Brian, additional, Samari, Ellaisha, additional, Wang, Peizhi, additional, Cetty, Laxman, additional, Satghare, Pratika, additional, Verma, Swapna K, additional, Tang, Charmaine, additional, and Subramaniam, Mythily, additional

Published
2024
Full Text
View/download PDF

50. Clinical trajectories in the ultra-high risk for psychosis population

Author

Polari, Andrea, Lavoie, Suzie, Yuen, Hok-Pan, Amminger, Paul, Berger, Gregor, Chen, Eric, deHaan, Lieuwe, Hartmann, Jessica, Markulev, Connie, Melville, Fritha, Nieman, Dorien, Nordentoft, Merete, Riecher-Rössler, Anita, Smesny, Stefan, Stratford, John, Verma, Swapna, Yung, Alison, McGorry, Patrick, and Nelson, Barnaby

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results